<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675346</url>
  </required_header>
  <id_info>
    <org_study_id>19/SC/0554</org_study_id>
    <secondary_id>261224</secondary_id>
    <nct_id>NCT04675346</nct_id>
  </id_info>
  <brief_title>Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors</brief_title>
  <acronym>EUNASS</acronym>
  <official_title>Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ninewells Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centred cohort study whereby the EUNASS Study questionnaire will&#xD;
      be administered electronically to identify needs of melanoma survivors, the extent to which&#xD;
      these needs are being met, and identify areas which have the greatest need for development.&#xD;
      It will also evaluate behaviour in relation to sun protection and skin self-examination&#xD;
      (SSE). It will be a self-completed questionnaire.&#xD;
&#xD;
      Qualitative work using semi-structured interviews will explore the needs of melanoma&#xD;
      survivors in greater depth, will present examples of potential interventions to improve SSE&#xD;
      and explore factors that determine the likelihood of engaging in an intervention which can&#xD;
      address unmet needs, such as improving SSE. Taken together, the data will provide the&#xD;
      evidence base to inform the development of an intervention to improve SSE, which can&#xD;
      subsequently be tested in secondary care services.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">November 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mixed methods: analysis of a) Patient questionnaire responses and b) Semi-structured interviews</measure>
    <time_frame>2 years</time_frame>
    <description>Mixed methods analysis - quantitative and qualitative results</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Melanoma, Stage I</condition>
  <condition>Melanoma Stage III</condition>
  <condition>Melanoma, Stage II</condition>
  <arm_group>
    <arm_group_label>Questionnaire</arm_group_label>
    <description>The EUNASS Study Questionnaire is an electronic questionnaire (using the Qualtrics programme) designed to assess management after diagnosis of melanoma and during follow-up, health status, fear of melanoma recurrence, melanoma-specific supportive care needs, sun protection behaviour, views and habits about SSE and standard socio-demographic details.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interviews</arm_group_label>
    <description>A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire</description>
    <arm_group_label>Interviews</arm_group_label>
    <arm_group_label>Questionnaire</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending the Dermatology or Medical Oncology departments with a confirmed&#xD;
        diagnosis of AJCC V8 stage I - III melanoma in the last year&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participant is willing and able to give informed consent for participation in the study.&#xD;
&#xD;
          -  Male or Female, aged 18 years or above.&#xD;
&#xD;
          -  Histological diagnosis of primary cutaneous invasive melanoma (any Breslow thickness)&#xD;
             at 3 - 12 months from diagnosis (as most primary treatment will be complete by 3 mths)&#xD;
&#xD;
          -  American Joint Cancer Committee Version 8 [2018] (AJCC V8) Stage I - III melanoma at&#xD;
             time of recruitment&#xD;
&#xD;
          -  Able to complete an electronic questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other current active internal malignancy (i.e. does not include non-melanoma skin&#xD;
             cancers)&#xD;
&#xD;
          -  Inability to independently complete electronic questionnaire&#xD;
&#xD;
          -  AJCC V8 Stage IV melanoma at time of recruitment&#xD;
&#xD;
          -  Clinical stage of disease unknown / unconfirmed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubeta Matin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Westmoreland</last_name>
    <phone>01865 228252</phone>
    <email>melanie.westmoreland@ouh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rubeta Matin, FRCP</last_name>
    <email>rubeta.matin@ouh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubeta N Matin, PhD FRCP</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oxford University Hospitals NHS Trust</investigator_affiliation>
    <investigator_full_name>Rubeta Matin</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

